Latest news
Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 to pre-clinical development
Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX), a …Read more »
Calendar
- Interim Report January – June 2017August 23, 2017
- Pareto Securities Health Care Seminar, StockholmSeptember 7, 2017
CEO statement
We are very enthusiastic about the rapid progress of our 4-1BB (CD137) antibody ATOR-1017. This is our third immuno-oncology asset to enter pre-clinical development and it demonstrates the strength and breadth of our pipeline. Read more
Donation for research on pancreatic cancer in memory of Jerker Löfgren
In light of our ambition to develop novel cancer therapeutics, Alligator has received a donation for research on pancreatic cancer in memory of Jerker Löfgren. We are honored by the confidence shown for our research within immuno-oncology and our hope is that this will come to benefit patients with pancreatic cancer over time.